том 11 издание 8 страницы 2566-2578

Pluronics and MDR Reversal: An Update

Тип публикацииJournal Article
Дата публикации2014-07-10
SCImago Q1
WOS Q1
БС1
SJR0.957
CiteScore7.8
Impact factor4.5
ISSN15438384, 15438392
Drug Discovery
Pharmaceutical Science
Molecular Medicine
Краткое описание
Multidrug resistance (MDR) remains one of the biggest obstacles for effective cancer therapy. Currently there are only few methods that are available clinically that are used to bypass MDR with very limited success. In this review we describe how MDR can be overcome by a simple yet effective approach of using amphiphilic block copolymers. Triblock copolymers of poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), arranged in a triblock structure PEO-PPO-PEO, Pluronics or “poloxamers”, raised a considerable interest in the drug delivery field. Previous studies demonstrated that Pluronics sensitize MDR cancer cells resulting in increased cytotoxic activity of Dox, paclitaxel, and other drugs by 2–3 orders of magnitude. Pluronics can also prevent the development of MDR in vitro and in vivo. Additionally, promising results of clinical studies of Dox/Pluronic formulation reinforced the need to ascertain a thorough understanding of Pluronic effects in tumors. These effects are extremely comprehensive and appear on the level of plasma membranes, mitochondria, and regulation of gene expression selectively in MDR cancer cells. Moreover, it has been demonstrated recently that Pluronics can effectively deplete tumorigenic intrinsically drug-resistant cancer stem cells (CSC). Interestingly, sensitization of MDR and inhibition of drug efflux transporters is not specific or selective to Pluronics. Other amphiphilic polymers have shown similar activities in various experimental models. This review summarizes recent advances of understanding the Pluronic effects in sensitization and prevention of MDR.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Для доступа к списку профилей, цитирующих публикацию, необходимо авторизоваться.

Топ-30

Журналы

1
2
3
4
5
6
7
International Journal of Pharmaceutics
7 публикаций, 3.41%
Journal of Controlled Release
7 публикаций, 3.41%
Langmuir
7 публикаций, 3.41%
Journal of Molecular Liquids
6 публикаций, 2.93%
Polymers
5 публикаций, 2.44%
Molecular Pharmaceutics
5 публикаций, 2.44%
Pharmaceutics
4 публикации, 1.95%
Biomaterials
4 публикации, 1.95%
ACS applied materials & interfaces
3 публикации, 1.46%
Journal of Colloid and Interface Science
3 публикации, 1.46%
Journal of Drug Delivery Science and Technology
3 публикации, 1.46%
Macromolecular Bioscience
3 публикации, 1.46%
ACS Nano
3 публикации, 1.46%
Journal of Materials Chemistry B
3 публикации, 1.46%
Pharmaceutical Research
2 публикации, 0.98%
ACS Applied Polymer Materials
2 публикации, 0.98%
Nanomedicine
2 публикации, 0.98%
Nanomaterials
2 публикации, 0.98%
Antioxidants
2 публикации, 0.98%
Drug Delivery and Translational Research
2 публикации, 0.98%
AAPS PharmSciTech
2 публикации, 0.98%
Colloids and Surfaces B: Biointerfaces
2 публикации, 0.98%
European Journal of Pharmaceutical Sciences
2 публикации, 0.98%
Advanced Drug Delivery Reviews
2 публикации, 0.98%
Colloids and Surfaces A: Physicochemical and Engineering Aspects
2 публикации, 0.98%
Nanomedicine: Nanotechnology, Biology, and Medicine
2 публикации, 0.98%
Macromolecular Rapid Communications
2 публикации, 0.98%
Advanced healthcare materials
2 публикации, 0.98%
Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology
2 публикации, 0.98%
1
2
3
4
5
6
7

Издатели

10
20
30
40
50
60
70
Elsevier
69 публикаций, 33.66%
American Chemical Society (ACS)
31 публикация, 15.12%
Springer Nature
22 публикации, 10.73%
Wiley
19 публикаций, 9.27%
MDPI
17 публикаций, 8.29%
Taylor & Francis
13 публикаций, 6.34%
Royal Society of Chemistry (RSC)
11 публикаций, 5.37%
Bentham Science Publishers Ltd.
2 публикации, 0.98%
Frontiers Media S.A.
2 публикации, 0.98%
Public Library of Science (PLoS)
2 публикации, 0.98%
Hindawi Limited
2 публикации, 0.98%
Pleiades Publishing
1 публикация, 0.49%
Impact Journals
1 публикация, 0.49%
SAGE
1 публикация, 0.49%
Korean Society of Industrial Engineering Chemistry
1 публикация, 0.49%
Federation of American Societies for Experimental Biology (FASEB)
1 публикация, 0.49%
American Physiological Society
1 публикация, 0.49%
SciELO
1 публикация, 0.49%
openRxiv
1 публикация, 0.49%
Trans Tech Publications
1 публикация, 0.49%
OAE Publishing Inc.
1 публикация, 0.49%
AIP Publishing
1 публикация, 0.49%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 публикация, 0.49%
10
20
30
40
50
60
70
  • Мы не учитываем публикации, у которых нет DOI.
  • Статистика публикаций обновляется еженедельно.

Вы ученый?

Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
 Войти с ORCID
Метрики
205
Поделиться
Цитировать
ГОСТ |
Цитировать
Alakhova D. Y., Kabanov A. Pluronics and MDR Reversal: An Update // Molecular Pharmaceutics. 2014. Vol. 11. No. 8. pp. 2566-2578.
ГОСТ со всеми авторами (до 50) Скопировать
Alakhova D. Y., Kabanov A. Pluronics and MDR Reversal: An Update // Molecular Pharmaceutics. 2014. Vol. 11. No. 8. pp. 2566-2578.
RIS |
Цитировать
TY - JOUR
DO - 10.1021/mp500298q
UR - https://doi.org/10.1021/mp500298q
TI - Pluronics and MDR Reversal: An Update
T2 - Molecular Pharmaceutics
AU - Alakhova, Daria Y
AU - Kabanov, A.A.
PY - 2014
DA - 2014/07/10
PB - American Chemical Society (ACS)
SP - 2566-2578
IS - 8
VL - 11
PMID - 24950236
SN - 1543-8384
SN - 1543-8392
ER -
BibTex |
Цитировать
BibTex (до 50 авторов) Скопировать
@article{2014_Alakhova,
author = {Daria Y Alakhova and A.A. Kabanov},
title = {Pluronics and MDR Reversal: An Update},
journal = {Molecular Pharmaceutics},
year = {2014},
volume = {11},
publisher = {American Chemical Society (ACS)},
month = {jul},
url = {https://doi.org/10.1021/mp500298q},
number = {8},
pages = {2566--2578},
doi = {10.1021/mp500298q}
}
MLA
Цитировать
Alakhova, Daria Y., et al. “Pluronics and MDR Reversal: An Update.” Molecular Pharmaceutics, vol. 11, no. 8, Jul. 2014, pp. 2566-2578. https://doi.org/10.1021/mp500298q.
Ошибка в публикации?